0000000000133110

AUTHOR

Enrique Rey

showing 3 related works from this author

Supplementary_Material – Supplemental material for Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome…

2019

Supplemental material, Supplementary_Material for Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms by Blanca Serrano-Falcón, Sílvia Delgado-Aros, Fermín Mearin, Constanza Ciriza de los Ríos, Jordi Serra, Miguel Mínguez, Miguel Montoro Huguet, Antonia Perelló, Cecilio Santander, Ángeles Pérez Aisa, Inmaculada Bañón-Rodríguez and Enrique Rey in Therapeutic Advances in Gastroenterology

FOS: Clinical medicine111199 Nutrition and Dietetics not elsewhere classifiedFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified111299 Oncology and Carcinogenesis not elsewhere classified
researchProduct

Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive an…

2019

Background:Linaclotide is approved for the treatment of moderate-to-severe irritable bowel syndrome (IBS) with constipation (IBS-C) in adults. This study aimed to assess factors predictive of a clinical response and improvements in non-IBS symptoms with linaclotide treatment in a Spanish patient population.Methods:In this open-label phase IIIb study, patients with moderate-to-severe IBS-C received linaclotide 290 μg once daily for 12 weeks. The primary endpoint was clinical response at week 12, defined as >30% reduction in IBS symptom severity score (IBS-SSS) or IBS-SSS <75 plus self-reported response of feeling ‘better’ or ‘much better’ versus the baseline. Digestive nonintestinal an…

Abdominal painmedicine.medical_specialtyConstipation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinefunctional gastrointestinal diseasesmedicinelcsh:RC799-869LinaclotideIrritable bowel syndromeOriginal Researchirritable bowel syndromebusiness.industryGastroenterologyabdominal painconstipationmedicine.diseasechemistry030220 oncology & carcinogenesisSustained response030211 gastroenterology & hepatologylcsh:Diseases of the digestive system. Gastroenterologymedicine.symptombusinessTherapeutic Advances in Gastroenterology
researchProduct

Optimizing the use of linaclotide in patients with constipation-predominant irritable bowel syndrome : an expert consensus report

2017

INTRODUCTION: Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by chronic or recurrent abdominal pain in association with defecation or a change in bowel habits. A predominant disorder of bowel habits, IBS is classified into three main subtypes: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D) and IBS alternating between constipation and diarrhea (IBS-M). Linaclotide is a first-in-class, oral, once-daily guanylate cyclase-C receptor agonist (GC-CA) that is licensed for the symptomatic treatment of moderate-to-severe IBS-C in adults. This review aims to facilitate and optimize clinical practices, establishing common guidelines to monitor patie…

medicine.medical_specialtyAbdominal painAbdominal painConstipationReviewRecommendationsGastroenterologyIrritable Bowel Syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBloatingGastrointestinal AgentsInternal medicinemedicineHumansPharmacology (medical)030212 general & internal medicineLinaclotideGastroenterologiaIrritable bowel syndromeMedicine(all)business.industryBloatingGastroenterologyIntestins -- MalaltiesGeneral Medicinemedicine.diseaseSíndrome do Intestino IrritávelRheumatologyDiarrheaTreatment OutcomechemistryDefecationLinaclotide030211 gastroenterology & hepatologyPatient managementmedicine.symptomConstipation-predominant irritable bowel syndromebusinessPeptidesReceptors Atrial Natriuretic FactorConstipation
researchProduct